Global RNAi Technology Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global RNAi Technology Market Research Report 2024
RNA interference is a relatively new concept in the field of medicine. It is a process in which the ribonucleic acid inhibits translation or gene expression by converting single-stranded mRNA to double stranded RNA, thereby neutralizing the target nucleic acids.
According to MRAResearch’s new survey, global RNAi Technology market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole RNAi Technology market research.
As an important force driving a new round of scientific and technological revolution, artificial intelligence has been of national strategic importance. Many governments introduces polices and increase capital investment to support AI companies. The Digital Europe plan adopted by the European Union will allocate €9.2 billion on high-tech investments, such as supercomputing, artificial intelligence, and network security. In order to maintain its leading position, the United States will increase its investment in artificial intelligence research and development in non-defense fields, from US$1.6 billion to US$1.7 billion in 2022. According to the latest data released by IDC, global artificial intelligence revenue was US$432.8 billion in 2022, a year-on-year increase of 19.97%, including software, hardware and services.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global RNAi Technology market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Alnylam Pharmaceuticals
Dicerna Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc.
Arbutus Biopharma
Benitec Biopharma
Calando
Silence Therapeutics
Gotham Therapeutics
Segment by Type
Cancer
Liver Disorders
Respiratory Disorders
Neurological Disorders
Autoimmune Disorders
Others
Drug Discovery & Development
Therapeutics
Drug Delivery
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The RNAi Technology report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global RNAi Technology market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole RNAi Technology market research.
As an important force driving a new round of scientific and technological revolution, artificial intelligence has been of national strategic importance. Many governments introduces polices and increase capital investment to support AI companies. The Digital Europe plan adopted by the European Union will allocate €9.2 billion on high-tech investments, such as supercomputing, artificial intelligence, and network security. In order to maintain its leading position, the United States will increase its investment in artificial intelligence research and development in non-defense fields, from US$1.6 billion to US$1.7 billion in 2022. According to the latest data released by IDC, global artificial intelligence revenue was US$432.8 billion in 2022, a year-on-year increase of 19.97%, including software, hardware and services.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global RNAi Technology market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Alnylam Pharmaceuticals
Dicerna Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc.
Arbutus Biopharma
Benitec Biopharma
Calando
Silence Therapeutics
Gotham Therapeutics
Segment by Type
Cancer
Liver Disorders
Respiratory Disorders
Neurological Disorders
Autoimmune Disorders
Others
Segment by Application
Drug Discovery & Development
Therapeutics
Drug Delivery
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The RNAi Technology report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source